PTGS2 and cancer: Given that COX-2 inhibitors have demonstrated antitumor activity across various cancers, the binding of C3G to PTGS2 suggests that it may modulate cancer-promoting pathways, reducing inflammation and inhibiting cancer cell survival by disrupting the inflammatory and proliferative signals mediated by PTGS2.